Modularit

About Modularit

Modularit offers an AI‑driven platform that designs interchangeable, modular receptor components for in vivo cell therapies, enabling rapid reconfiguration of ligand‑binding, signaling, and safety domains. The system generates high‑affinity, manufacturable receptors that integrate with viral or non‑viral delivery methods, reducing development time, manufacturing complexity, and cost for biotech and pharma programs targeting cancer, autoimmunity, and fibrosis.

<problem>Cell therapies often rely on engineered receptors that are difficult to design, costly to produce, and can exhibit safety or efficacy limitations, restricting their use across oncology, autoimmunity, and fibrotic diseases.</problem> <solution>Modularit provides a platform that creates interchangeable, modular receptor components for in vivo cell therapies. An AI‑driven protein design engine generates receptor variants optimized for binding specificity, signaling strength, and manufacturability. The modular architecture allows rapid swapping of ligand‑binding domains, signaling modules, and safety switches to tailor therapies for different disease targets. Produced receptors are engineered for stable expression in patient‑derived cells, reducing manufacturing complexity and enabling scalable, cost‑effective treatment pipelines. The platform integrates with existing cell‑therapy workflows, delivering validated receptor libraries that accelerate preclinical development and de‑risk clinical translation.</solution> <features> - AI‑based protein design pipeline that predicts high‑affinity binding and optimal signaling profiles - Fully modular receptor architecture separating targeting, signaling, and safety domains for rapid reconfiguration - Built‑in safety switches (e.g., inducible apoptosis, cytokine release control) to mitigate adverse events - Compatibility with viral and non‑viral delivery methods for in vivo cell engineering - Scalable production workflow that reduces reagent costs and accelerates GMP manufacturing - Comprehensive validation suite including in vitro potency assays and in vivo efficacy models </features> <target_audience>Primary customers are biotech firms and pharmaceutical R&D groups developing engineered cell therapies for cancer, autoimmune disorders, and fibrotic conditions.</target_audience>

What does Modularit do?

Modularit offers an AI‑driven platform that designs interchangeable, modular receptor components for in vivo cell therapies, enabling rapid reconfiguration of ligand‑binding, signaling, and safety domains. The system generates high‑affinity, manufacturable receptors that integrate with viral or non‑viral delivery methods, reducing development time, manufacturing complexity, and cost for biotech and pharma programs targeting cancer, autoimmunity, and fibrosis.

Where is Modularit located?

Modularit is based in Montreal, Canada.

When was Modularit founded?

Modularit was founded in 2021.

How much funding has Modularit raised?

Modularit has raised $500.0K.

Who founded Modularit?

Modularit was founded by David Cotnoir-White and Etienne Gagnon.

  • David Cotnoir-White - CEO/Co-Founder
  • Etienne Gagnon - Co-Founder/CSO
Location
Montreal, Canada
Founded
2021
Funding
$500.0K
Employees
10 employees
Investors
Y Combinator
M

Modularit

Modularit offers an AI‑driven platform that designs interchangeable, modular receptor components for in vivo cell therapies, enabling rapid reconfiguration of ligand‑binding, signaling, and safety domains. The system generates high‑affinity, manufacturable receptors that integrate with viral or non‑viral delivery methods, reducing development time, manufacturing complexity, and cost for biotech and pharma programs targeting cancer, autoimmunity, and fibrosis.

Montreal, CanadaFounded 2021101K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 2 months ago

Funding

$500.0K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Cell therapies often rely on engineered receptors that are difficult to design, costly to produce, and can exhibit safety or efficacy limitations, restricting their use across oncology, autoimmunity, and fibrotic diseases.

Solution

Modularit provides a platform that creates interchangeable, modular receptor components for in vivo cell therapies. An AI‑driven protein design engine generates receptor variants optimized for binding specificity, signaling strength, and manufacturability. The modular architecture allows rapid swapping of ligand‑binding domains, signaling modules, and safety switches to tailor therapies for different disease targets. Produced receptors are engineered for stable expression in patient‑derived cells, reducing manufacturing complexity and enabling scalable, cost‑effective treatment pipelines. The platform integrates with existing cell‑therapy workflows, delivering validated receptor libraries that accelerate preclinical development and de‑risk clinical translation.

Target Audience

Primary customers are biotech firms and pharmaceutical R&D groups developing engineered cell therapies for cancer, autoimmune disorders, and fibrotic conditions.

Features

  • AI‑based protein design pipeline that predicts high‑affinity binding and optimal signaling profiles
  • Fully modular receptor architecture separating targeting, signaling, and safety domains for rapid reconfiguration
  • Built‑in safety switches (e.g., inducible apoptosis, cytokine release control) to mitigate adverse events
  • Compatibility with viral and non‑viral delivery methods for in vivo cell engineering
  • Scalable production workflow that reduces reagent costs and accelerates GMP manufacturing
  • Comprehensive validation suite including in vitro potency assays and in vivo efficacy models
1
This profile is AI-generated and may contain inaccuracies.